{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 7 of 60', 'Table 3-2', 'Study VX18-445-109: Treatment Period and Safety Follow-up Visit', 'TEZ/IVA Run-in', 'Safety', 'Period (4 weeks)', 'Treatment Period (24 weeks)', 'Follow-up', 'Visit', 'Day -14', '(28 7 Days', '(Day -15', 'After Last', 'Event/', 'Day -28', 'to', 'Day 15', 'Week 4', 'Week 8', 'Week 12', 'Week 16', 'Week 20', 'Week 24', 'ETT', 'Dose of', 'Assessment', '1 day', 'Day -3)', 'Day 1d', '3 days', '5 days', '5 days', '5 days', '5 days', '5 days', '5 days', 'Visitb', 'Study Drug)', 'Comments', 'Clinic visit', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Telephone contact', 'X', 'X', \"Assess the subject's status,\", 'any AEs, concomitant', 'medications, treatments, and', 'procedures.', 'Inclusion and', 'X', 'exclusion criteria', 'confirmation', 'CFQ-R', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Completed before any other', 'assessments scheduled at', 'relevant visits (Section', '11.4.1).', 'Weight and height', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Measured with shoes off.', 'Height will only be collected', 'for subjects 21 years of age', 'on the date of informed', 'consent (Section 11.4.3).', 'Ophthalmologic', 'X', 'X', 'Subjects <18 years of age on', 'examination', 'the date of informed consent', 'and who completed at least', '12 weeks of study drug', 'treatment will have a single', 'ophthalmologic examination', 'at either the ETT or Week 24', 'Visit, whichever comes first', '(Section 11.5.6).', 'Complete physical', 'X', 'X', 'X', 'X', 'X', 'Symptom directed physical', 'examination', 'examinations may be', 'performed at any time if', 'deemed necessary by the', 'investigator (Section 11.5.3).', 'a', 'All assessments will be performed before dosing unless noted otherwise.', 'b', 'If a subject prematurely discontinues study drug treatment, an ETT Visit should be scheduled as soon as possible after the decision to discontinue treatment. Subjects who prematurely discontinue', 'treatment during the Treatment Period will continue to complete all scheduled study visits for assessments following completion of the ETT Visit.', 'c', 'The Safety Follow-up Visit is required for all subjects, unless the subject completes the Week 24 Visit and has enrolled in a separate open-label study within 28 days after the last dose of study drug. If', 'an ETT Visit occurs 3 weeks or later following the last dose of study drug, then the ETT Visit replaces the Safety Follow-up Visit.', 'd', 'To enter the Treatment Period, conditions for entry must be satisfied.', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 8 of 60', 'Table 3-2', 'Study VX18-445-109: Treatment Period and Safety Follow-up Visit', 'TEZ/IVA Run-in', 'Safety', 'Period (4 weeks)', 'Treatment Period (24 weeks)', 'Follow-up', 'Visit', 'Day -14', '(28 7 Days', '(Day -15', 'After Last', 'Event/', 'Day -28', 'to', 'Day 15', 'Week 4', 'Week 8', 'Week 12', 'Week 16', 'Week 20', 'Week 24', 'ETT', 'Dose of', 'Assessment', '1 day', 'Day -3)', 'Day 1d', '3 days', '5 days', '5 days', '5 days', '5 days', '5 days', '5 days', 'Visit', 'Study Drug)', 'Comments', 'Pregnancy testing', 'urine', 'urine', 'urine', 'urine', 'urine', 'urine', 'urine', 'urine', 'urine', 'serum', 'serum', 'At telephone contacts, a urine', '(all female', 'pregnancy test will be', 'subjects)', 'performed with a home kit', 'provided by the study site.', 'Results will be reported to the', 'site by telephone.', 'Standard 12-lead', 'X', 'X', 'X', 'X', 'X', 'X', 'Performed after subject has', 'ECG', 'been at rest for at least', '5 minutes (Section 11.5.5).', 'Vital signs and', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Performed after subject has', 'pulse oximetry', 'been at rest for at least', '5 minutes (Sections 11.5.3', 'and 11.5.4).', 'Spirometry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Should be performed', 'pre-bronchodilator and at', 'approximately the same time', 'at each visit (Section 11.4.2).', 'Sweat chloride', 'X', 'X', 'X', 'X', 'X', 'X', 'At each time point, 2 samples', 'will be collected (1 from each', 'arm, Section 11.3).', 'Urinalysis', 'X', 'X', 'X', 'X', 'Hematology', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Coagulation', 'X', 'X', 'X', 'X', 'X', 'Serum chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Run-in TEZ/IVA', 'Day -28 to evening', 'dosing', 'on Day 1', 'Run-in TEZ/IVA', 'X', 'X', 'X', 'drug count', 'Randomization', 'X', 'May occur on Day -1 or', 'Day 1 after eligibility for', 'entry into the Treatment', 'Period has been satisfied.', 'Randomized study', 'Day 1 through evening before Week 24 Visit', 'drug dosing', 'Randomized study', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'drug count', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}